Revised overall survival analysis of a phase II, randomized, double-blind, controlled study of PROSTVAC in men with metastatic castration-resistant prostate cancer

Journal of Clinical Oncology

Volumn 35, Issue 1, 2017, Pages 124-125

  Kantoff, Philip W ^a   Gulley, James L ^b   Pico Navarro, Cesar ^c  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c Bavarian Nordic GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; METRONIDAZOLE; RILIMOGENE GALVACIREPVEC; CANCER VACCINE;

CASTRATION RESISTANT PROSTATE CANCER; FOLLOW UP; HUMAN; LETTER; METASTASIS; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); BIOLOGICAL THERAPY; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DOUBLE BLIND PROCEDURE; IMMUNOTHERAPY; MALE; MORTALITY; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; REPRODUCIBILITY; STATISTICS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

BIOLOGICAL THERAPY; CANCER VACCINES; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; FOLLOW-UP STUDIES; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IMMUNOTHERAPY; MALE; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; REPRODUCIBILITY OF RESULTS; STATISTICS AS TOPIC; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 85009860282     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2016.69.7748     Document Type: Letter

References (1)

1. Kantoff PW, Schuetz TJ, Blumenstein BA, et al: Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol 28: 1099-1105, 2010